118 related articles for article (PubMed ID: 20417938)
1. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence.
Rawnaq T; Schwarzenbach H; Schurr PG; Freise K; Brandl S; Izbicki JR; Kaifi JT
J Surg Res; 2011 Jul; 169(1):31-5. PubMed ID: 20417938
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of loss of heterozygosity in serum microsatellite DNA of patients with gastrointestinal stromal tumors.
Schurr PG; Oikonomou D; Kaifi JT; Merkert P; Wolter S; Kleinhans H; Reichelt U; Mann O; Gawad KA; Strate T; Yekebas EF; Izbicki JR
J Clin Gastroenterol; 2009 Jan; 43(1):27-35. PubMed ID: 18469721
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite DNA alterations of gastrointestinal stromal tumors are predictive for outcome.
Schurr P; Wolter S; Kaifi J; Reichelt U; Kleinhans H; Wachowiak R; Yekebas E; Strate T; Kalinin V; Simon R; Sauter G; Schaefer H; Izbicki J
Clin Cancer Res; 2006 Sep; 12(17):5151-7. PubMed ID: 16951233
[TBL] [Abstract][Full Text] [Related]
4. A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
Schwarzenbach H; Müller V; Beeger C; Gottberg M; Stahmann N; Pantel K
Breast Cancer Res; 2007; 9(5):R66. PubMed ID: 17915011
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.
Schwarzenbach H; Eichelser C; Kropidlowski J; Janni W; Rack B; Pantel K
Clin Cancer Res; 2012 Oct; 18(20):5719-30. PubMed ID: 23014523
[TBL] [Abstract][Full Text] [Related]
6. Heterozygosity loss at 22q and lack of INI1 gene mutation in gastrointestinal stromal tumor.
Yamamoto H; Kohashi K; Tsuneyoshi M; Oda Y
Pathobiology; 2011; 78(3):132-9. PubMed ID: 21613800
[TBL] [Abstract][Full Text] [Related]
7. Effect of loss of heterozygosity of the c-kit gene on prognosis after hepatectomy for metastatic liver gastrointestinal stromal tumors.
Kikuchi H; Yamamoto M; Hiramatsu Y; Baba M; Ohta M; Kamiya K; Tanaka T; Suzuki S; Sugimura H; Kitagawa M; Kanai T; Kitayama Y; Kanda T; Nishikura K; Konno H
Cancer Sci; 2007 Nov; 98(11):1734-9. PubMed ID: 17894554
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients.
Taback B; Fujiwara Y; Wang HJ; Foshag LJ; Morton DL; Hoon DS
Cancer Res; 2001 Aug; 61(15):5723-6. PubMed ID: 11479206
[TBL] [Abstract][Full Text] [Related]
9. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.
Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517
[TBL] [Abstract][Full Text] [Related]
10. Detection of microsatellite alterations in plasma DNA of malignant mucosal melanoma using whole genome amplification.
Nakamoto D; Yamamoto N; Takagi R; Katakura A; Mizoe JE; Shibahara T
Bull Tokyo Dent Coll; 2008 May; 49(2):77-87. PubMed ID: 18776719
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors.
Hunt JL; Yim JH; Tometsko M; Finkelstein SD; Swalsky P; Carty SE
Surgery; 2003 Dec; 134(6):1043-7; discussion 1047-8. PubMed ID: 14668739
[TBL] [Abstract][Full Text] [Related]
12. Loss of chromosome 9p21 and decreased p16 expression correlate with malignant gastrointestinal stromal tumor.
Zhang Y; Cao H; Wang M; Zhao WY; Shen ZY; Shen DP; Ni XZ; Wu ZY; Shen YY; Song YY
World J Gastroenterol; 2010 Oct; 16(37):4716-24. PubMed ID: 20872974
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer.
Wang Q; Larson PS; Schlechter BL; Zahid N; Finnemore E; de las Morenas A; Blanchard RA; Rosenberg CL
Int J Cancer; 2003 Oct; 106(6):923-9. PubMed ID: 12918071
[TBL] [Abstract][Full Text] [Related]
14. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
Schwarzenbach H; Chun FK; Lange I; Carpenter S; Gottberg M; Erbersdobler A; Friedrich MG; Huland H; Pantel K
Int J Cancer; 2007 Apr; 120(7):1465-71. PubMed ID: 17205532
[TBL] [Abstract][Full Text] [Related]
15. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
Schwarzenbach H; Müller V; Stahmann N; Pantel K
Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
Schwarzenbach H; Pantel K; Kemper B; Beeger C; Otterbach F; Kimmig R; Kasimir-Bauer S
Breast Cancer Res; 2009; 11(5):R71. PubMed ID: 19772563
[TBL] [Abstract][Full Text] [Related]
17. Allelic loss of Hox11L1 gene locus predicts outcome of gastrointestinal stromal tumors.
Kaifi JT; Wagner M; Schurr PG; Wachowiak R; Reichelt U; Yekebas EF; Mann O; Vashist Y; Kleinhans H; Link BC; Strate T; Kalinin V; Izbicki JR
Oncol Rep; 2006 Oct; 16(4):915-9. PubMed ID: 16969514
[TBL] [Abstract][Full Text] [Related]
18. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
Fromont G; Valeri A; Cher M; Pontes JE; Vallancien G; Validire P; Latil A; Cussenot O
Prostate; 2005 Dec; 65(4):341-6. PubMed ID: 16015610
[TBL] [Abstract][Full Text] [Related]
19. LOH analysis of free DNA in the plasma of patients with mucosal malignant melanoma in the head and neck.
Takagi R; Nakamoto D; Mizoe JE; Tsujii H
Int J Clin Oncol; 2007 Jun; 12(3):199-204. PubMed ID: 17566843
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of preoperative molecular serum analysis in renal cancer.
Gonzalgo ML; Eisenberger CF; Lee SM; Trock BJ; Marshall FF; Hortopan S; Sidransky D; Schoenberg MP
Clin Cancer Res; 2002 Jun; 8(6):1878-81. PubMed ID: 12060631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
